AGLE Aeglea BioTherapeutics Inc

Price (delayed)

$7.09

Market cap

$347.87M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.01

Enterprise value

$316.55M

Aeglea BioTherapeutics is a clinical-stage biotechnology company redefining the potential of human enzyme therapeutics to benefit people with rare and devastating metabolic diseases with limited treatment options. Aeglea's lead product ...

Highlights
AGLE's EPS has soared by 56% YoY and by 23% QoQ
The net income has increased by 21% year-on-year and by 18% since the previous quarter
Aeglea BioTherapeutics's quick ratio has decreased by 37% YoY but it has increased by 37% QoQ
The company's equity fell by 22% YoY and by 3.8% QoQ
Aeglea BioTherapeutics's debt has increased by 7% YoY

Key stats

What are the main financial stats of AGLE
Market
Shares outstanding
49.06M
Market cap
$347.87M
Enterprise value
$316.55M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
2.92
Price to sales (P/S)
33.98
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
23.11
Earnings
Revenue
$13.7M
EBIT
-$65.7M
EBITDA
-$63.79M
Free cash flow
-$54.16M
Per share
EPS
-$1.01
Free cash flow per share
-$0.83
Book value per share
$2.43
Revenue per share
$0.21
TBVPS
$2.24
Balance sheet
Total assets
$146.98M
Total liabilities
$27.96M
Debt
$5.29M
Equity
$119.02M
Working capital
$113.76M
Liquidity
Debt to equity
0.04
Current ratio
6.52
Quick ratio
6.33
Net debt/EBITDA
0.49
Margins
EBITDA margin
-465.7%
Gross margin
100%
Net margin
-480.4%
Operating margin
-480.5%
Efficiency
Return on assets
-41.9%
Return on equity
-50.7%
Return on invested capital
-87.9%
Return on capital employed
-52%
Return on sales
-479.7%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

AGLE stock price

How has the Aeglea BioTherapeutics stock price performed over time
Intraday
1.43%
1 week
-0.14%
1 month
10.09%
1 year
-7.56%
YTD
-9.91%
QTD
1.87%

Financial performance

How have Aeglea BioTherapeutics's revenue and profit performed over time
Revenue
$13.7M
Gross profit
$13.7M
Operating income
-$65.81M
Net income
-$65.8M
Gross margin
100%
Net margin
-480.4%
Aeglea BioTherapeutics's operating income has increased by 22% YoY and by 18% QoQ
The net income has increased by 21% year-on-year and by 18% since the previous quarter

Growth

What is Aeglea BioTherapeutics's growth rate over time

Valuation

What is Aeglea BioTherapeutics stock price valuation
P/E
N/A
P/B
2.92
P/S
33.98
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
23.11
AGLE's EPS has soared by 56% YoY and by 23% QoQ
AGLE's P/B is 22% above its 5-year quarterly average of 2.4 and 8% above its last 4 quarters average of 2.7
The company's equity fell by 22% YoY and by 3.8% QoQ

Efficiency

How efficient is Aeglea BioTherapeutics business performance
The company's return on equity rose by 49% YoY and by 13% QoQ
Aeglea BioTherapeutics's ROA has increased by 47% YoY and by 15% from the previous quarter
AGLE's return on invested capital is up by 35% year-on-year and by 18% since the previous quarter

Dividends

What is AGLE's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for AGLE.

Financial health

How did Aeglea BioTherapeutics financials performed over time
AGLE's current ratio is up by 39% QoQ but it is down by 36% YoY
Aeglea BioTherapeutics's quick ratio has decreased by 37% YoY but it has increased by 37% QoQ
Aeglea BioTherapeutics's debt is 96% lower than its equity
AGLE's debt to equity is up by 33% year-on-year
The company's equity fell by 22% YoY and by 3.8% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.